Lifeboat Foundation

Elon Musk was challenged to fix South Australia’s energy problem in 2017, and just two years on he’s saved Australians millions.

Elon Musk is bulking up his rocket-building workforce—big time. Ars Technica visited the Texas home of SpaceX, where Musk was calling a meeting on a Sunday “morning” at 1 a.m. There’s a lot to unpack here.

To start, Musk is worried that our window of opportunity to make it to Mars is closing—so we better hurry up. After the 1 a.m. meeting, SpaceX added over 250 new employees in two days, representing a full doubling of the workforce.

Ars Technica visited the day after the major Starship prototype implosion that made news earlier this week. The SN1 prototype blew up as a direct result of weak welds. It sounds like everyone involved knew this prototype was faulty and told Musk so when he asked, and he insists it was never designed to fly for real anyway.

Advocates for diversity in STEM have a saying: You can’t be what you can’t see. We need to do a better job of celebrating the accomplishments of underrepresented scientists, so that the next generation can more easily imagine themselves joining the ranks of the scientific community.

To close out Black History Month, we wanted to take a moment to highlight just a few of the many incredible black scientists we’ve featured so far on the show. Their bios are below, along with links to the episodes they appear in.

On Short Wave we strive to make the diversity of our guests reflect the diversity of our audience. If there’s a scientist from an underrepresented group that you know of who’s doing awesome science and you think we should feature them in an episode, drop us a line at [email protected].

Finding new medicines is like finding a needle in a haystack. By linking a powerful computational approach to advances in chemical manufacturing, this company is making piles of needles.

Artificial intelligence (AI) and machine learning are increasingly becoming a part of drug discovery and development beginning with identifying new compounds to structuring and designing clinical trials and targeting clinical trial populations.

A recent example came out of Linköping University in Sweden. The investigators utilized an artificial neural network to create maps of biological networks based on how different genes or proteins interact with each other. They leveraged a large database with information about the expression patterns of 20,000 genes in a large group of people. The AI was then taught to find patterns of gene expression.

And in mid-February, a drug developed using AI began testing in human clinical trials. The molecule, DSP-1181, is currently in Phase I clinical trials for obsessive-compulsive disorder. The compound is a long-acting potent serotonin 5-HT1A receptor agonist developed using AI that was part of a collaboration between Japan’s Sumitomo Dainippon Pharma and the UK’s Escientia. The AI developed the compound in about 12 months, compared to a more typical five-year process.

Fossils of rangeomorphs, which dominated the oceans more than a half-billion years ago, show the thin threads that connected them.

Sonovia’s textiles are resistant to bacteria and fungus; firm hopes its tech will also work against viruses; has sent samples for testing to China.

The incredible shot of the rare phenomenon, captured above Calbuco volcano in southern Chile, won first prize in “The Perfect Moment” photo competition.

Would you want to know if you’re at risk of Alzheimer’s disease, for example?

The integration of sequencing into health care doesn’t fit very well in the model of how medicine is practiced today, but is well aligned with the future vision of health care that so many of us have — a vision that focuses upon prediction and prevention.

Continue reading “Genome Sequencing for Healthy People: Is it Time?” »